Released Nov 6, 2025, after the close
10-Q filed Nov 6, 2025, 37 days after period end · 0001193125-25-270036
Q3 2025 · 10-Q
Revenue$9.69M$9.69M +13.8% vs Q3 2024−84.8% vs Q2 2025
Net Income-$56.86M-$56.86M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$6.66-$6.66 N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$48,459,000N/M
Operating Cash Flowderived-$38,189,000N/M
Margins · derived
Operating margin-499.9%+297.2 pt vs Q3 2024
Net margin-586.6%−14.0 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $9.69M | $8.52M | $16.92M | $25.15M |
| Net Income | -$56.86M | -$48.79M | -$49.28M | -$19.49M |
| EPS Diluted | -$6.66 | -$0.59 | -$0.81 | -$0.37 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR